STX2

Across TCGA pan-cancer cohorts, STX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STX2 data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STX2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STX2 expression acts as an unfavorable survival marker.

HNSC, LUAD, and UCEC are the cancer types where STX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.128	0.710	.001	18	view →
LUAD	OS	Median	III,IV	0.004	0.662	<.001	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.360	0.727	.034	5	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STX2–HNSC (DFS)

Open the HNSC breakdown →